Table 2 Differentially regulated transcripts.

Calcium Binding

ANXA11

Annexin A11

L19605

10q23

97.6 ± 9.1

39.1 ± 1.8

89%

2.5 ± 0.2

2.8E–02

1.5E–05

6.0E–04

1.954

S100A4

S100 calcium binding protein A4

M80563

1q21

213.2 ± 19.9

87.6 ± 7.8

89%

2.4 ± 0.2

3.2E–02

5.3E–05

5.3E–03

S100A12

S100 calcium binding protein A12

D83657

1q21

65.4 ± 14.0

22.8 ± 4.8

67%

2.6 ± 0.8

5.2E–01

3.3E–03

—

CALM3

Calmodulin 3

J04046

19q13.2–q13.3

29.6 ± 1.8

13.8 ± 1.0

67%

2.1 ± 0.1

6.9E–02

4.7E–06

1.1E–04

CACYBP

Calcyclin binding protein

BC001431

1q24–q25

179.2 ± 23.4

72.2 ± 8.3

67%

2.3 ± 0.5

1.1E–01

4.0E–04

—

Chaperone

HYOU1

Hypoxia up-regulated 1

U65785

11q23.1–q23.3

33.7 ± 3.6

11.4 ± 0.7

78%

3.0 ± 0.3

4.2E–02

2.0E–05

1.1E–03

NAP1L4

Nucleosome assembly protein 1-like 4

U77456

11p15.5

26.6 ± 3.6

9.8 ± 0.8

78%

2.7 ± 0.4

5.7E–02

1.9E–04

3.3E–02

TTC1

Tetratricopeptide repeat domain 1

U46570

5q32–q33.2

41.7 ± 4.7

16.1 ± 1.3

67%

2.6 ± 0.3

2.9E–02

5.3E–05

5.4E–03

DNAJC7

DnaJ (Hsp40) homolog, subfamily C, member 7

U46571

17q11.2

17.8 ± 2.3

6.5 ± 0.5

67%

2.7 ± 0.3

1.6E–01

1.0E–04

1.2E–02

Cytokine/chemokine

IGF2

Insulin growth factor 2 gene, intron 7

S73149

34.1 ± 4.9

8.9 ± 0.7

89%

3.8 ± 0.5

8.0E–02

1.9E–05

1.0E–03

1.874

CSF1

Human macrophage-specific colony-stimulating factor

M11296

1p21–p13

28.0 ± 3.6

9.6 ± 0.7

78%

2.9 ± 0.4

9.6E–02

4.3E–05

3.7E–03

CCL5

Chemokine (C-C motif) ligand 5

M21121

17q11.2–q12

156.8 ± 14.9

53.7 ± 3.7

78%

2.9 ± 0.3

2.7E–02

2.5E–05

1.5E–03

CCL22

Chemokine (C-C motif) ligand 22

U83239

16q13

31.2 ± 5.0

11.2 ± 0.9

67%

2.8 ± 0.4

1.3E–01

4.4E–04

—

CCL22 (duplicate)

Chemokine (C-C motif) ligand 22

U83171

16q13

15.2 ± 2.1

6.2 ± 0.2

67%

2.5 ± 0.3

1.8E–02

6.3E–04

—

TGFB1

Transforming growth factor, β 1

M38449

19q13.2

26.6 ± 4.0

10.1 ± 1.1

67%

2.4 ± 0.6

7.2E–03

1.3E–03

—

MLN

Motilin

X15393

6p21.3

13.4 ± 1.8

6.0 ± 0.4

67%

2.2 ± 0.3

9.5E–02

8.9E–04

—

PF4

Platelet factor 4 (chemokine (C-X-C motif) ligand 4)

M25897

4q12–q21

278.3 ± 14.2

136.5 ± 13.7

56%

2.0 ± 0.1

1.2E–01

1.2E–05

4.7E–04

IL7R

Interleukin 7 receptor

M29696

5p13

24.0 ± 10.8

30.2 ± 9.6

67%

−2.3 ± 1.0

1.3E–01

—

—

DNA binding

HMGB1

High-mobility group box 1

D63874

13q12

83.2 ± 9.3

27.3 ± 4.3

78%

3.0 ± 0.3

2.5E–01

3.3E–05

2.6E–03

MKRN4

Ring zinc-finger protein

U41315

Xp21.1

15.0 ± 1.9

5.8 ± 0.3

67%

2.6 ± 0.3

1.3E–01

3.1E–04

—

HIST2H2AA

Histone 2, H2aa

L19779

1q21.3

71.9 ± 8.2

32.9 ± 3.0

56%

2.2 ± 0.2

5.2E–02

6.6E–05

7.2E–03

DDB1

Damage-specific DNA binding protein 1

U32986

1lq12–q13

24.7 ± 3.3

11.0 ± 0.6

67%

2.0 ± 0.5

6.2E–02

1.5E–03

—

Enzyme

LYZ

Lysozyme

M21119

12q14.3

53.0 ± 27.2

69.2 ± 20.0

67%

−6.6 ± 2.2

8.0E–02

—

—

AGPAT1

1-acylglycerol-3-phosphate O-acyltransferase 1

U56417

6p21.3

26.3 ± 2.7

7.2 ± 0.4

89%

3.7 ± 0.4

6.6E–02

3.1E–05

2.3E–03

2.006

DIA1

NADH-cytochrome b5 reductase

M28713

33.3 ± 3.4

8.9 ± 0.5

100%

3.7 ± 0.4

5.1E–02

2.5E–06

3.7E–05

2.462

KIAA0220

Pl-3-kinase-related kinase SMG-1-like

D86974

16p12.2

239.2 ± 33.3

73.4 ± 8.9

78%

3.3 ± 0.5

1.5E–02

1.2E–04

1.6E–02

GSTZ1

Glutathione transferase zeta 1

U86529

14q24.3

25.6 ± 3.3

7.8 ± 0.6

78%

3.3 ± 0.4

1.0E–01

2.5E–05

1.5E–03

PYGB

Phosphorylase, glycogen

U47025

20p11.2–p11.1

25.2 ± 2.7

7.8 ± 0.4

89%

3.2 ± 0.3

5.1E–02

1.3E–04

1.9E–02

SAT

Spermidine/spermine N1-acetyltransferase

U40369

Xp22.1

37.7 ± 4.0

12.3 ± 2.0

89%

3.1 ± 0.3

4.1E–01

1.9E–05

9.6E–04

UROD

Uroporphyrinogen decarboxylase

X89267

1p34

42.7 ± 6.2

14.2 ± 1.1

78%

3.0 ± 0.4

1.1E–01

2.1E–04

3.7E–02

GPI

Glucose phosphate isomerase

K03515

19q13.1

35.8 ± 4.5

12.1 ± 1.0

67%

3.0 ± 0.4

2.3E–02

3.3E–05

2.6E–03

GSTO1

Glutathione S-transferase omega 1

U90313

10q25.1

43.2 ± 4.2

14.3 ± 1.5

89%

3.0 ± 0.3

8.9E–02

5.4E–06

1.4E–04

DDX11

DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11

U75968

12p11

20.6 ± 2.8

7.1 ± 0.6

100%

2.9 ± 0.4

6.3E–02

1.5E–05

6.7E–04

IMPDH1

MP (inosine monophosphate) dehydrogenase 1

J05272

7q31.3–q32

31.4 ± 4.7

10.9 ± 0.9

78%

2.9 ± 0.4

3.7E–02

2.3E–04

4.3E–02

PIB5PA

Phosphatidylinositol (4,5) bisphosphate 5-phosphatase, A

U45975

22q11.2–q13.2

20.0 ± 2.6

7.2 ± 0.4

67%

2.8 ± 0.4

6.6E–02

2.7E–04

—

CNP

2′,3′-cyclic nucleotide 3′ phosphodiesterase

D13146

17q21

49.9 ± 6.4

17.8 ± 1.4

78%

2.8 ± 0.4

1.3E–01

4.9E–05

4.8E–03

UPP1

Uridine Phosphorylase 1

X90858

7p12.3

21.4 ± 1.3

7.6 ± 0.6

89%

2.8 ± 0.2

5.1E–02

2.4E–07

6.1E–07

2.246

AMPD2

Adenosine monophosphate deaminase 2 (isoform L)

M91029

1p13.3

30.3 ± 4.0

11.2 ± 0.8

78%

2.7 ± 0.4

6.6E–02

8.6E–05

9.8E–03

BCAT2

Branched chain aminotransferase 2, mitochondrial

U62739

19q13

18.8 ± 2.0

7.1 ± 0.3

78%

2.7 ± 0.3

3.1E–02

1.0E–04

1.2E–02

HSD17B3

Hydroxysteroid (17-beta) dehydrogenase 3

U05659

9q22

21.4 ± 2.6

8.1 ± 0.5

78%

2.7 ± 0.3

8.0E–02

1.6E–04

2.5E–02

GARS

Glycyl-tRNA synthetase

U09587

7p15

29.7 ± 2.5

11.2 ± 0.7

78%

2.7 ± 0.2

7.6E–02

3.7E–06

7.1E–05

PTGS1

Prostaglandin-endoperoxide synthase 1

M59979

9q32–q33.3

14.2 ± 2.3

5.5 ± 0.4

67%

2.6 ± 0.4

7.9E–02

1.6E–03

—

TGM1

Transglutaminase 1

L34840

14q11.2, 3p22–p21.33

18.4 ± 2.3

7.2 ± 0.7

67%

2.6 ± 0.3

1.9E–01

9.2E–05

1.1E–02

AOAH

Acyloxyacyl hydrolase

M62840

7p14–p12

25.2 ± 5.4

9.2 ± 0.8

67%

2.5 ± 0.7

2.3E–01

4.8E–03

—

GNPDA1

Glucosamine-6-phosphate deaminase 1

D31766

5q21

13.8 ± 2.0

5.5 ± 0.3

56%

2.5 ± 0.4

6.7E–02

6.4E–04

—

AARS

Alanyl-tRNA synthetase

D32050

16q22

18.1 ± 2.5

7.4 ± 0.3

67%

2.5 ± 0.3

1.6E–01

9.7E–04

—

SETDB1

SET domain, bifurcated 1

D31891

1q21

18.6 ± 2.5

7.4 ± 0.7

67%

2.5 ± 0.3

8.9E–02

1.5E–04

2.3E–02

DCTD

Deoxycytidylate deaminase gene

L39874

4q35.1

25.0 ± 3.0

9.8 ± 0.8

67%

2.5 ± 0.3

8.0E–02

5.4E–05

5.5E–03

HUMNOSB

Inducible nitric oxide synthase

D29675

14.1 ± 2.6

5.3 ± 0.2

67%

2.4 ± 0.6*

2.6E–01

4.1E–03

—

MGLL

Monoglyceride lipase

U67963

3q21.3

18.9 ± 2.0

7.2 ± 0.5

89%

2.4 ± 0.5

9.8E–02

2.3E–04

4.4E–02

DAO

D-amino-acid oxidase

D11370

12q24

14.9 ± 2.2

6.2 ± 0.2

56%

2.4 ± 0.4

9.7E–02

1.1E–03

—

DDT

D-dopachrome tautomerase

U49785

22q11.23

24.9 ± 2.9

10.5 ± 0.6

56%

2.4 ± 0.3

4.9E–02

1.1E–04

1.5E–02

TPI1

Triosephosphate isomerase 1

M10036

12p13

73.3 ± 8.5

30.0 ± 2.6

78%

2.4 ± 0.3

2.7E–02

1.0E–04

1.3E–02

SULT1A3

Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3

U20499

16p11.2

20.3 ± 2.3

8.3 ± 0.6

67%

2.4 ± 0.3

1.7E–01

7.6E–05

8.5E–03

GLA

Galactosidase, alpha

X14448

Xq22

20.6 ± 2.2

8.6 ± 0.9

78%

2.4 ± 0.3

2.8E–01

1.0E–04

1.3E–02

PPGB

Protective protein for β-galactosidase

M22960

20q13.1

83.4 ± 8.6

35.2 ± 2.4

78%

2.4 ± 0.2

2.6E–02

4.9E–05

4.8E–03

FAH

Fumarylacetoacetate hydrolase

M55150

15q23–q25

18.7 ± 1.1

7.9 ± 0.5

89%

2.4 ± 0.1

4.4E–02

6.8E–07

3.4E–06

2.008

CDA

Cytidine deaminase

L27943

1p36.2–p35

26.9 ± 5.8

10.5 ± 1.0

56%

2.3 ± 0.7

6.4E–02

4.6E–03

—

HYAL2

Hyaluronoglucosaminidase 2

AJ000099

3p21.3

24.9 ± 3.7

10.9 ± 0.8

67%

2.3 ± 0.3

6.4E–02

1.7E–03

—

INPP5D

Inositol polyphosphate-5-phosphatase

U57650

2q36–q37

42.8 ± 5.6

18.8 ± 1.3

67%

2.3 ± 0.3

8.9E–02

4.6E–04

—

CES1

Carboxylesterase 1

L07765

16q13–q22.1

14.0 ± 2.0

6.2 ± 0.2

56%

2.3 ± 0.3

1.0E–01

1.2E–03

—

ACADVL

Acyl-Coenzyme A dehydrogenase

D43682

17p13–p11

41.4 ± 3.8

18.2 ± 1.6

67%

2.3 ± 0.2

2.0E–02

3.2E–05

2.4E–03

SULT1A1

Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1

L19999

16p12.1

21.0 ± 2.3

9.2 ± 1.1

56%

2.3 ± 0.2

2.9E–01

9.3E–05

1.1E–02

PRDX6

Peroxiredoxin 6

D14662

1q24.1

36.4 ± 2.7

16.1 ± 2.1

67%

2.3 ± 0.2

1.0E–01

4.4E–05

4.0E–03

UQCRC1

Ubiquinol-cytochrome c reductase core protein

L16842

3p21.3

24.1 ± 3.3

10.1 ± 0.8

78%

2.2 ± 0.5

7.5E–02

5.4E–04

—

GUSB

Glucuronidase, beta

M15182

7q21.11

18.9 ± 2.2

8.5 ± 0.5

56%

2.2 ± 0.3

4.9E–02

1.2E–04

1.6E–02

HK3

Hexokinase 3

U51333

5q35.2

47.1 ± 7.3

20.0 ± 2.0

56%

2.1 ± 0.5

3.4E–01

1.6E–03

—

CHKL

Choline kinase-like

U62317

22q13.33

60.8 ± 7.0

26.6 ± 1.5

67%

2.1 ± 0.4

1.1E–01

5.0E–04

—

PGM1

Phosphoglucomutase 1

M83088

1p31

16.7 ± 1.5

7.8 ± 0.5

56%

2.1 ± 0.2

2.4E–01

4.6E–05

4.2E–03

PCSK6

Proprotein convertase subtilisin/kexin type 6

M80482

15q26

10.7 ± 1.1

5.1 ± 0.1

44%

2.1 ± 0.2

3.7E–02

1.7E–04

2.6E–02

PMM1

Phosphomannomutase 1

U86070

22q13.2

13.8 ± 1.3

6.6 ± 0.2

56%

2.1 ± 0.2

3.6E–02

1.7E–04

2.7E–02

TALDO1

Transaldolase 1

L19437

11p15.5–p15.4

85.3 ± 9.9

37.7 ± 3.0

78%

2.0 ± 0.5

1.2E–01

6.4E–04

—

Extracellular matrix

EPB49

Erythrocyte membrane protein band 4.9 (dematin)

L19713

8p21.1

38.7 ± 4.3

9.9 ± 0.8

100%

3.9 ± 0.4

2.8E–02

3.1E–06

5.2E–05

2.064

SPARC

Secreted protein, acidic, cysteine-rich (osteonectin)

J03040

5q31.3–q32

57.8 ± 8.2

24.4 ± 3.5

56%

2.4 ± 0.3

1.1E–01

4.0E–04

—

Integral intracellular membrane

CPT1B

Carnitine palmitoyltransferase 1B (muscle)

Y08682

22q13.33

13.6 ± 1.9

4.9 ± 0.2

67%

2.8 ± 0.4

8.0E–02

3.3E–04

—

STX5A

Syntaxin 5A

U26648

11q12.3

19.9 ± 2.2

7.9 ± 0.6

89%

2.5 ± 0.3

1.8E–02

1.9E–05

9.0E–04

HAX1

HS1 binding protein

U68566

1q22

31.0 ± 2.9

13.9 ± 1.2

67%

2.2 ± 0.2

7.7E–02

4.9E–05

4.6E–03

BAP1

BRCA1 associated protein-1

D87462

3p21.31–p21.2

12.9 ± 1.0

6.2 ± 0.3

56%

2.1 ± 0.2

1.4E–02

5.4E–05

5.6E–03

BZRP

Benzodiazapine receptor (peripheral)

L21954

22q13.31

127.9 ± 26.1

50.5 ± 4.3

56%

2.3 ± 0.6

1.9E–01

4.8E–03

—

BCL2

B-cell CLL/lymphoma 2

M14745

18q21.33

16.2 ± 2.1

7.5 ± 0.6

44%

1.9 ± 0.5

1.4E–01

8.0E–04

—

HERPUD1

Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1

D14695

16q12.2–q13

16.6 ± 3.1

7.0 ± 0.6

56%

1.9 ± 0.7

4.2E–01

7.8E–03

—

Integral plasma membrane

STAB1

Stabilin 1

D87433

3p21.31

30.2 ± 6.7

4.7 ± 0.2

100%

6.4 ± 1.4*

1.8E–01

6.3E–05

6.8E–03

2.164

IGHG3

Immunoglobulin heavy constant γ 3

M87789

14q32.33

105.6 ± 38.7

15.8 ± 2.5

67%

6.3 ± 2.6

1.2E–01

1.4E–02

—

ZYX

Zyxin

X95735

7q32

38.0 ± 6.5

10.5 ± 1.0

78%

3.6 ± 0.6

4.1E–02

4.7E–04

—

SELPLG

Selectin P ligand

U25956

12q24

75.9 ± 10.0

21.1 ± 1.8

78%

3.6 ± 0.5

4.4E–02

2.2E–05

1.3E–03

PRF1

Perforin

M31951

10q22

16.9 ± 6.6

25.0 ± 3.8

67%

−3.4 ± 1.2

1.0E + 00

—

—

CD151

CD151 antigen

D29963

11p15.5

29.2 ± 4.9

8.7 ± 0.8

78%

3.4 ± 0.6

2.9E–01

1.3E–04

1.8E–02

CD63

CD63 antigen

X62654

12q12–q13

41.8 ± 6.7

12.4 ± 1.3

89%

3.4 ± 0.5

1.4E–01

1.0E–04

1.2E–02

IFNGR2

Interferon γ receptor 2

U05875

21q22.11

37.9 ± 6.9

11.5 ± 1.1

56%

3.3 ± 0.6

1.3E–01

3.4E–04

—

TRIP12

Thyroid hormone receptor interactor 12

D28476

2q37.1

27.4 ± 3.7

8.9 ± 1.0

78%

3.1 ± 0.4

2.4E–01

1.4E–04

2.1E–02

LENG4

Leukocyte receptor cluster member 4

S82470

19q13.4

26.8 ± 3.9

8.7 ± 0.6

78%

3.1 ± 0.4

8.6E–02

1.6E–04

2.5E–02

CSF3R

Colony stimulating factor 3 receptor

M59820

1p35–p34.3

33.3 ± 6.9

10.2 ± 0.8

67%

3.0 ± 0.8

5.9E–02

4.2E–03

—

GP1BB

Glycoprotein lb (platelet), β polypeptide

U59632

22q11.21

97.2 ± 16.2

30.5 ± 3.3

67%

3.0 ± 0.7

6.9E–02

7.1E–04

—

FLOT2

Flotillin 2

M60922

17q11–q12

50.4 ± 7.9

16.1 ± 1.2

78%

2.8 ± 0.7

2.8E–02

3.9E–03

—

VAT1

Vesicle amine transport protein 1 homolog

U18009

17q21

12.3 ± 1.2

4.5 ± 0.1

78%

2.8 ± 0.3*

1.1E–01

2.5E–05

1.6E–03

2.327

MCL1

Myeloid cell leukemia sequence 1

L08246

1q21

88.7 ± 9.7

32.2 ± 3.9

78%

2.8 ± 0.3

6.6E–02

5.7E–05

6.0E–03

HIA-DQA1

Major histocompatibility complex, class II, DQα 1

M34996

6p21.3

80.6 ± 18.7

25.1 ± 3.7

56%

2.7 ± 1.0

2.2E–01

6.8E–03

—

MICB

MHC class I chain-related gene B

U65416

6p21.3

17.3 ± 2.1

6.5 ± 0.2

67%

2.7 ± 0.3

1.2E–01

2.0E–04

3.5E–02

CD7

CD7 antigen

D00749

17q25.2–q25.3

69.9 ± 8.8

25.8 ± 2.1

67%

2.7 ± 0.3

4.3E–03

1.7E–04

2.9E–02

LILRA2

Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2

U82275

19q13.4

25.4 ± 4.7

8.8 ± 0.8

67%

2.6 ± 0.7

1.4E–01

2.1E–03

—

HEM1

Hematopoietic protein 1

M58285

12q13.1

38.4 ± 5.1

14.6 ± 2.0

67%

2.6 ± 0.3

1.2E–01

1.7E–04

2.7E–02

FCGRT

Fc fragment of IgG, receptor, transporter, alpha

U12255

19q13.3

78.6 ± 13.7

29.2 ± 2.5

67%

2.5 ± 0.6

1.1E–01

2.8E–03

—

SPG7

Spastic paraplegia 7 homolog

X65784

16q24.3

21.6 ± 2.2

8.5 ± 0.5

78%

2.5 ± 0.3

6.4E–02

3.2E–05

2.4E–03

IL10RB

Interleukin 10 receptor, beta

Z17227

21q22.1–q22.2

15.8 ± 1.6

6.2 ± 0.4

78%

2.5 ± 0.3

3.7E–02

3.6E–05

2.9E–03

SELF

Selectin P

M25322

1q22–q25

15.0 ± 1.2

5.9 ± 0.4

78%

2.5 ± 0.2

1.0E–01

1.5E–06

1.4E–05

2.018

CEACAM4

Carcinoembryonic antigen-related cell adhesion molecule 4

D90276

19q13.2

13.3 ± 2.1

5.5 ± 0.2

56%

2.4 ± 0.4*

5.8E–02

1.7E–03

—

CD3E

CD3E antigen, epsilon polypeptide

M23323

11q23

45.8 ± 5.8

18.9 ± 1.0

67%

2.4 ± 0.3

4.0E–02

4.0E–04

—

AAMP

Angio-associated, migratory cell protein

M95627

2q35

22.1 ± 3.2

9.4 ± 0.7

56%

2.4 ± 0.3

5.1E–02

1.1E–03

—

LAMP1

Lysosomal-associated membrane protein 1

J04182

13q34

47.8 ± 4.5

20.2 ± 2.0

67%

2.4 ± 0.2

7.4E–02

3.3E–05

2.6E–03

BST2

Bone marrow stromal cell antigen 2

D28137

19p13.2

46.3 ± 9.5

16.4 ± 1.6

78%

2.3 ± 0.8

2.5E–01

9.3E–03

—

CD33

CD33 antigen

M23197

19q13.3

19.4 ± 3.1

7.6 ± 0.7

56%

2.3 ± 0.5

2.3E–01

1.3E–03

—

ACRV1

Intra-acrosomal protein

S65583

11p12–q13

12.8 ± 2.3

5.5 ± 0.2

56%

2.3 ± 0.4*

7.3E–02

2.9E–03

—

PTTG1IP

Pituitary tumor-transforming 1 interacting protein

Z50022

21q22.3

30.0 ± 3.3

13.0 ± 0.9

56%

2.3 ± 0.3

6.0E–02

1.7E–04

2.7E–02

HDLBP

High density lipoprotein binding protein (vigilin)

M64098

2q37

18.8 ± 2.3

8.3 ± 0.6

67%

2.3 ± 0.3

5.3E–02

2.9E–04

—

ICAM3

Intercellular adhesion molecule 3

X69819

19p13.3–p13.2

52.2 ± 4.4

22.6 ± 1.7

67%

2.3 ± 0.2

8.2E–03

2.0E–05

1.1E–03

OS-9

Amplified in osteosarcoma

U41635

12q13

58.6 ± 7.7

24.2 ± 1.8

67%

2.2 ± 0.5

8.3E–02

9.9E–04

—

EMP3

Epithelial membrane protein 3

U52101

19q13.3

159.3 ± 21.9

65.2 ± 4.9

67%

2.2 ± 0.5

1.5E–03

1.1E–03

—

HA-1

Minor histocompatibility antigen HA-1

D86976

19p13.3

103.1 ± 11.3

43.5 ± 2.0

78%

2.2 ± 0.4

3.5E–02

1.7E–04

2.8E–02

EBI3

Epstein-Barr virus induced gene 3

L08187

19p13.3

12.8 ± 1.7

5.8 ± 0.2

56%

2.2 ± 0.3

3.1E–02

5.4E–04

—

SPN

Sialophorin

M61827

16p11.2

33.2 ± 4.5

15.0 ± 1.3

67%

2.2 ± 0.3

8.3E–02

6.9E–04

—

CD19

CD19 antigen

M84371

16p11.2

14.6 ± 1.3

6.7 ± 0.3

67%

2.2 ± 0.2

1.0E–02

1.1E–04

1.5E–02

ITGAX

Integrin, α X

M81695

16p11.2

32.2 ± 4.8

13.8 ± 1.0

44%

2.1 ± 0.5

2.1E–01

1.1E–03

—

P2RX5

Purinergic receptor P2X, ligand-gated ion channel, 5

U49395

17p13.3

17.4 ± 1.8

8.2 ± 0.7

56%

2.1 ± 0.2

3.1E–02

1.7 E–04

2.8E–02

HLA-DOA

Major histocompatibility complex, class II, DO alpha

M31525

6p21.3

13.6 ± 1.6

6.4 ± 0.4

56%

2.1 ± 0.2

7.8E–02

3.5E–04

—

KLRK1

Killer cell lectin-like receptor subfamily K, member 1

X54870

12p13.2–p12.3

31.3 ± 3.8

13.4 ± 1.5

67%

2.0 ± 0.5

1.2E–03

6.8E–04

—

ITGB2

Integrin, β 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1

M15395

21q22.3

86.1 ± 7.9

37.8 ± 3.9

78%

2.0 ± 0.4

1.2E–01

1.8E–04

3.1E–02

LAPTM5

Lysosomal-associated multispanning membrane protein-5

U51240

1p34

146.9 ± 21.8

61.8 ± 5.4

67%

1.9 ± 0.6

1.2E–01

2.8E–03

—

Mitochondrial

UCP2

Uncoupling protein 2

U94592

11

50.2 ± 6.6

22.5 ± 2.0

56%

2.0 ± 0.5

4.8E–03

7.9E–04

—

Other

IER2

Immediate early response 2

M62831

19p13.13

105.7 ± 17.3

28.7 ± 1.7

78%

3.5 ± 0.7

6.4E–02

3.7E–04

—

PTMA

Prothymosin, alpha

M14483

2q35–q36

65.9 ± 17.1

109.3 ± 8.0

44%

−3.4 ± 1.5

9.7E–01

3.9E–02

—

CRIP2

Cysteine-rich protein 2

D42123

14q32.3

25.6 ± 3.2

8.1 ± 0.6

78%

3.2 ± 0.4

1.5E–01

1.1E–04

1.4E–02

PHC2

Polyhomeotic-like 2

U89278

1p34.3

23.4 ± 3.0

7.8 ± 0.3

89%

3.0 ± 0.4

6.3E–02

1.7E–04

2.7E–02

FTH1

Ferritin, heavy polypeptide 1

L20941

11q13

279.0 ± 16.1

122.8 ± 5.7

67%

2.3 ± 0.1

2.9E–02

2.4E–07

7.2E–07

2.452

PFC

Properdin P factor, complement

M83652

Xp11.3–p11.23

46.6 ± 8.4

19.1 ± 1.8

56%

2.2 ± 0.6

1.8E–01

1.2E–02

—

IFI44

Interferon-induced protein 44

D28915

1p31.1

13.6 ± 2.5

5.5 ± 0.3

56%

2.0 ± 0.7

7.2E–01

5.5E–03

—

Proteases or inhibitors

PCOLN3

Procollagen (type III) N-endopeptidase

U58048

16q24.3

17.3 ± 2.3

5.4 ± 0.2

78%

3.2 ± 0.4

8.0E–02

1.4E–04

2.0E–02

MME

Membrane metallo-endopeptidase

J03779

3q25.1–q25.2

24.6 ± 3.4

7.8 ± 0.7

67%

3.1 ± 0.4

2.2E–01

1.9E–04

3.1E–02

ADAM8

A disintegrin and metalloproteinase domain 8

D26579

10q26.3

31.6 ± 4.1

10.6 ± 0.9

67%

3.0 ± 0.4

6.7E–02

4.9E–05

4.5E–03

SERPINB6

Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6

S69272

6p25

24.7 ± 2.8

8.7 ± 0.5

89%

2.8 ± 0.3

3.0E–02

1.9E–05

9.5E–04

TIMP2

Tissue inhibitor of metalloproteinase 2

M32304

17q25

25.7 ± 3.3

8.8 ± 0.8

78%

2.7 ± 0.5

6.2E–02

2.0E–04

3.3E–02

CTSD

Cathepsin D

M63138

11p15.5

82.9 ± 16.7

30.3 ± 2.0

56%

2.7 ± 0.6

6.4E–02

1.0E–03

—

SPINT2

Serine protease inhibitor, Kunitz type, 2

U78095

19q13.1

23.9 ± 1.9

10.5 ± 0.9

89%

2.3 ± 0.2

1.0E–01

7.2E–06

2.1E–04

NOMO1

PM5 protein, centromeric copy

X57398

16p13.11

27.3 ± 2.9

11.5 ± 0.9

78%

2.4 ± 0.2

5.6E–02

1.2E–04

1.5E–02

PSME1

Proteasome (prosome, macropain) activator subunit 1

L07633

14q11.2

84.3 ± 11.3

34.9 ± 3.2

56%

2.2 ± 0.5

1.1E–01

5.5E–04

—

PSMD2

Proteasome 26S subunit, non-ATPase, 2

D78151

3q27.3

36.2 ± 4.5

16.0 ± 1.2

56%

2.3 ± 0.3

1.3E–01

2.1 E–04

3.7E–02

CTSB

Cathepsin B

M14221

8p22

71.3 ± 11.1

29.8 ± 2.8

56%

2.1 ± 0.6

2.2E–01

6.6E–03

—

PSMA4

Proteasome subunit, a type, 4

D00763

15q24.1

42.8 ± 5.9

17.8 ± 2.6

67%

2.2 ± 0.5

2.9E–01

5.7E–04

—

Ribosomal

MRPL28

Mitochondrial ribosomal protein L28

U19796

16p13.3

22.0 ± 2.7

6.2 ± 0.3

100%

3.5 ± 0.4

1.2E–01

6.2E–06

1.7E–04

2.299

RPL39

Ribosomal protein L39

D79205

Xq22–q24

465.1 ± 21.5

226.3 ± 24.3

22%

2.1 ± 0.1

1.3E–01

1.9E–05

8.7E–04

RPS4Y1

Ribosomal protein S4, Y-linked 1

M58459

Yp11.3

15.1 ± 7.7

32.2 ± 6.4

78%

−5.5 ± 1.4

9.7E–01

—

—

Signal transduction

CSRP1

Cysteine and glycine-rich protein 1

M76378

1q32

21.0 ± 2.7

5.7 ± 0.4

89%

3.7 ± 0.5

1.3E–01

2.9E–05

2.0E–03

1.937

GNAZ

Guanine nucleotide binding protein (G protein), α z polypeptide

J03260

22q 11.22

24.9 ± 3.9

7.6 ± 0.5

67%

3.3 ± 0.5

1.0E–01

2.1 E–04

3.6E–02

CDC25B

Cell division cycle 25B

S78187

20p13

63.9 ± 8.5

19.1 ± 1.5

89%

3.3 ± 0.4

8.5E–02

5.6E–05

5.9E–03

ILK

Integrin-linked kinase

U40282

11p15.5–p15.4

29.2 ± 4.1

8.3 ± 0.7

78%

3.3 ± 0.7

5.6E–02

2.8E–04

—

PTPRN

Protein tyrosine phosphatase, receptor type, N

L18983

2q35–q36.1

20.8 ± 2.9

6.4 ± 0.4

78%

3.3 ± 0.5

9.5E–02

1.1E–04

1.4E–02

TSC2

Tuberous sclerosis 2

L48546

16p13.3

30.4 ± 3.3

9.2 ± 0.6

78%

3.3 ± 0.4

3.8E–02

1.2E–05

4.3E–04

1.984

BRD2

Bromodomain containing 2

X62083

6p21.3

70.9 ± 8.0

21.2 ± 2.8

78%

3.4 ± 0.4

1.2E–01

1.9E–05

9.8E–04

CLU

Clusterin

M63379

8p21–p12

222.8 ± 26.1

72.8 ± 6.8

78%

3.1 ± 0.4

3.6E–02

1.6E–05

7.2E–04

INPP5E

Inositol polyphosphate-5-phosphatase

U45974

9q34.3

15.1 ± 1.3

4.7 ± 0.2

89%

3.2 ± 0.3*

1.1E–01

3.9E–06

8.9E–05

2.575

LTK

Leukocyte tyrosine kinase

D16105

15q15.1–q21.1

23.8 ± 3.2

7.2 ± 0.8

89%

3.3 ± 0.4

4.1E–01

2.1E–05

1.2E–03

NRGN

Neurogranin

X99076

11q24

230.1 ± 27.2

76.5 ± 7.2

78%

3.0 ± 0.4

3.4E–02

2.5E–05

1.6E–03

PLCB2

Phospholipase C, β 2

M95678

15q15

84.0 ± 7.8

25.6 ± 1.9

100%

3.3 ± 0.3

1.9E–02

6.4E–07

2.6E–06

2.064

PKM2

Pyruvate kinase, muscle

X56494

15q22

60.0 ± 6.5

18.8 ± 1.5

78%

3.2 ± 0.3

1.3E–02

7.2E–06

2.2E–04

PSD

Pleckstrin and Sec7 domain containing

X99688

10q24

23.4 ± 3.7

7.8 ± 0.6

67%

3.0 ± 0.5

2.0E–01

2.8E–04

—

MAP2K3

Mitogen-activated protein kinase kinase 3

D87116

17q11.2

32.9 ± 4.1

11.2 ± 1.1

78%

2.9 ± 0.4

8.5E–02

4.9E–05

4.6E–03

IKBKE

Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon

D63485

1q32.1

18.9 ± 2.1

6.7 ± 0.4

78%

2.8 ± 0.3

1.2E–01

1.4E–04

2.0E–02

FASTK

FAST kinase

X86779

7q35

20.3 ± 2.4

7.0 ± 0.5

78%

2.9 ± 0.3

2.8E–02

8.5E–05

9.7E–03

LSP1

Lymphocyte-specific protein 1

M33552

11p15.5

48.1 ± 7.2

15.9 ± 1.8

78%

3.0 ± 0.5

4.5E–04

6.9E–05

7.5E–03

RABGGTA

Rab geranylgeranyltransferase, α subunit

Y08200

14q11.2

23.6 ± 3.1

8.6 ± 0.5

67%

2.7 ± 0.4

5.4E–02

1.4E–04

2.1E–02

MADD

MAP-kinase activating death domain

AB002356

11p11.2

31.7 ± 4.1

11.2 ± 0.7

67%

2.8 ± 0.4

1.5E–01

1.0E–04

1.3E–02

CSNK2A2

Casein kinase 2, α prime polypeptide

M55268

16p13.3–p13.2

17.3 ± 1.8

6.1 ± 0.2

78%

2.9 ± 0.3

1.7E–01

4.3E–05

3.8E–03

2.056

CCND3

Cyclin D3

M92287

6p21

68.3 ± 6.2

23.6 ± 2.3

78%

2.9 ± 0.3

5.0E–02

3.9E–06

8.5E–05

CENTB1

Centaurin, β 1

D30758

17p13.2

61.9 ± 6.3

22.6 ± 1.7

67%

2.7 ± 0.3

1.2E–02

2.5E–05

1.6E–03

PRKACG

Protein kinase, cAMP-dependent, catalytic, γ

M34182

9q13

41.6 ± 3.1

15.1 ± 1.5

89%

2.8 ± 0.2

1.2E–02

1.7E–06

2.2E–05

YWHAH

Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide

D78577

22q12.3

85.7 ± 5.7

31.1 ± 4.3

89%

2.8 ± 0.2

8.9E–02

2.8E–05

1.9E–03

NCF1

Neutrophil cytosolic factor 1

M55067

7q11.23

72.3 ± 13.7

22.1 ± 1.7

78%

3.1 ± 0.8

1.3E–02

1.2E–03

—

ARHGEF2

Rho/rac guanine nucleotide exchange factor 2

U72206

1q21–q22

25.6 ± 5.7

8.7 ± 0.7

56%

2.7 ± 0.8

2.9E–02

8.8E–03

—

TRAF1

TNF receptor-associated factor 1

U19261

9q33–q34

20.4 ± 2.6

7.3 ± 0.3

78%

2.6 ± 0.5

1.0E–01

3.4E–04

—

TRAF4

TNF receptor-associated factor 4

X80200

17q11–q12

15.1 ± 2.2

6.0 ± 0.3

56%

2.5 ± 0.4

6.0E–02

4.6E–04

—

ARAF1

V-raf murine sarcoma 3611 viral oncogene homolog

U01337

Xp11.4–p11.2

32.7 ± 2.8

11.8 ± 0.9

89%

2.8 ± 0.2

1.6E–02

1.6E–06

1.7E–05

CSK

C-src tyrosine kinase

X59932

15q23–q25

62.4 ± 8.0

22.5 ± 1.6

78%

2.8 ± 0.4

9.4E–03

1.2E–04

1.6E–02

FKBP4

FK506 binding protein 4, 59kDa

M88279

12p13.33

23.1 ± 3.2

8.8 ± 0.4

67%

2.6 ± 0.4

4.8E–02

4.8E–04

—

GNG10

Guanine nucleotide binding protein (G protein), γ 10

U31383

9q32

18.3 ± 3.0

6.7 ± 0.7

56%

2.7 ± 0.4

2.8E–01

3.7E–04

—

TNFRSF14

Tumor necrosis factor receptor superfamily, member 14

U70321

1p36.3–p36.2

28.1 ± 2.6

10.5 ± 0.7

78%

2.7 ± 0.2

7.5E–03

5.4E–06

1.4E–04

ARHGEF16

Rho guanine exchange factor 16

D89016

1p36.3

18.8 ± 3.0

6.6 ± 0.4

67%

2.6 ± 0.6

3.4E–01

2.9E–03

—

TNFRSF1B

Tumor necrosis factor receptor superfamily, member 1B

M32315

1p36.3–p36.2

67.4 ± 11.4

24.6 ± 2.6

67%

2.7 ± 0.5

4.9E–02

2.6E–04

4.9E–02

PIM1

Pim-1 oncogene

M16750

6p21.2

34.9 ± 4.5

13.9 ± 1.1

67%

2.3 ± 0.5

1.0E–01

6.0E–04

—

STK19

Serine/threonine kinase 19

BC016916

6p21.3

12.8 ± 1.5

5.4 ± 0.3

78%

2.4 ± 0.3*

4.3E–02

1.7E–04

2.8E–02

NDRG1

N-myc downstream regulated gene 1

D87953

8q24.3

39.6 ± 5.4

15.5 ± 1.1

67%

2.6 ± 0.3

1.3E–01

4.7E–04

—

PXN

Paxillin

U14588

12q24

39.1 ± 3.1

15.3 ± 1.8

89%

2.6 ± 0.2

4.2E–02

1.5E–05

6.7E–04

IHPK1

Inositol hexaphosphate kinase 1

D87452

3p21.31

14.1 ± 1.4

5.6 ± 0.2

67%

2.5 ± 0.2

2.4E–02

1.0E–04

1.3E–02

STAT5A

Signal transducer and activator of transcription 5A

U43185

17q11.2

27.6 ± 4.3

10.4 ± 0.8

78%

2.7 ± 0.4

5.4E–02

2.8E–04

—

SQSTM1

Sequestosome 1

U46751

5q35

98.8 ± 10.3

40.8 ± 2.5

67%

2.4 ± 0.3

1.6E–02

4.6E–05

4.1E–03

HDGF

Hepatoma-derived growth factor

BCO18991

X

41.6 ± 5.0

17.3 ± 1.6

67%

2.4 ± 0.3

8.6E–02

2.1E–04

3.7E–02

MPP1

Membrane protein, palmitoylated 1

M64925

Xq28

34,9 ± 4.9

15.5 ± 2.1

67%

2.2 ± 0.3

7.4E–01

7.1E–04

—

RGL2

Ral guanine nucleotide dissociation stimulator-like 2

U68142

6p21.3

15.7 ± 1.2

6.6 ± 0.3

78%

2.4 ± 0.2

4.5E–02

9.1E–06

3.1E–04

2.042

MX1

Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78

M33882

21q22.3

30.1 ± 8.8

8.7 ± 1.0

67%

3.0 ± 1.2

9.3E–01

1.4E–02

—

RPS6KA1

Ribosomal protein S6 kinase, 90kDa, polypeptide 1

L07597

3

28.8 ± 4.3

11.3 ± 1.1

67%

2.5 ± 0.4

1.2E–01

1.3E–04

1.8E–02

ITPK1

Inositol 1,3,4-triphosphate 5/6 kinase

U51336

14q31

49.0 ± 6.3

20.2 ± 1.4

56%

2.4 ± 0.3

5.7E–02

1.5E–04

2.2E–02

ARF3

ADP-ribosylation factor 3

M74491

12q13

54.1 ± 5.9

23.2 ± 2.7

56%

2.3 ± 0.3

5.7E–02

1.6E–04

2.4E–02

FKBP1A

FK506 binding protein 1A

M34539

20p13

42.8 ± 5.0

17.5 ± 1.3

67%

2.4 ± 0.3

1.9E–02

1.1E–04

1.4E–02

PRKAG1

Protein kinase, AMP-activated, γ 1 non-catalytic subunit

U42412

12q12–q14

15.4 ± 2.0

6.7 ± 0.3

67%

2.3 ± 0.3

5.4E–02

1.4E–03

—

BIRC1

Baculoviral IAP repeat-containing 1

U80017

5q12.2–q13.3

12.5 ± 1.5

5.8 ± 0.3

44%

2.1 ± 0.3

7.5E–02

2.3E–04

4.1E–02

ARHGEF1

Rho guanine nucleotide exchange factor 1

U64105

19q13.13

43.6 ± 3.7

19.2 ± 1.4

67%

2.3 ± 0.2

1.0E–02

1.5E–05

6.0E–04

AVPR1B

Arginine vasopressin receptor 1B

L37112

1q32

14.3 ± 1.4

6.4 ± 0.4

56%

2.2 ± 0.2

1.1E–01

5.8E–05

6.2E–3

DGKZ

Diacylglycerol kinase, zeta

U51477

11p11.2

32.6 ± 2.9

13.8 ± 0.8

67%

2.4 ± 0.2

2.8E–02

9.1E–06

3.2E–04

PARK7

Parkinson disease (autosomal recessive, early onset) 7

D61380

1p36.33–p36.12

58.4 ± 5.9

26.2 ± 3.0

56%

2.2 ± 0.2

1.3E–01

1.8E–04

2.9E–02

RGS2

G0/G1 switch regulatory gene # 8

L13391

1q31

60.3 ± 12.5

21.4 ± 3.2

67%

2.3 ± 0.8

2.7E–01

8.1E–03

—

PPM IF

Protein phosphatase 1F (PP2C domain containing)

D13640

22q11.22

29.0 ± 4.3

11.2 ± 1.0

67%

2.4 ± 0.6

1.7E–01

1.3E–03

—

ARF5

ADP-ribosylation factor 5

M57567

7q31.3

42.4 ± 6.2

16.2 ± 1.4

78%

2.4 ± 0.5

5.1E–02

4.0E–04

—

PTK2B

PTK2B protein tyrosine kinase 2 beta

U43522

8p21.1

13.2 ± 2.2

5.8 ± 0.3

56%

2.3 ± 0.4

5.0E–03

1.5E–03

—

PIM1

Pim-1 oncogene

M54915

6p21.2

54.7 ± 6.4

23.5 ± 1.8

78%

2.1 ± 0.4

1.1E–01

3.4E–04

—

INPPL1

Inositol polyphosphate phosphatase-like 1

L36818

11q23

19.4 ± 2.8

8.2 ± 0.9

56%

2.4 ± 0.3

1.3E–01

2.1E–04

3.8E–02

PCMT1

Protein-L-isoaspartate (D-aspartate) O-methyltransferase

D25547

6q24–q25

13.2 ± 2.3

5.8 ± 0.2

44%

2.3 ± 0.4

1.3E–01

1.4E–03

—

ARHGAP1

Rho GTPase activating protein 1

U02570

11p12–q12

25.6 ± 3.3

11.8 ± 0.8

56%

2.2 ± 0.3

3.4E–02

6.9E–04

—

FKBP2

FK506 binding protein 2, 13kDa

M75099

11q13.1–q13.3

23.6 ± 3.1

10.8 ± 0.9

56%

2.2 ± 0.3

7.0E–02

9.7E–04

—

TNIP1

TNFAIP3 interacting protein 1

D30755

5q32–q33.1

29.1 ± 4.0

12.8 ± 0.9

56%

2.3 ± 0.3

5.0E–02

2.2E–04

4.0E–02

IRAK1

Interleukin-1 receptor-associated kinase 1

L76191

Xq28

32.7 ± 2.8

15.5 ± 1.1

56%

2.1 ± 0.2

8.1E–02

2.0E–05

1.0E–03

RHOG

Ras homolog gene family, member G (rho G)

X61587

11p15.5–p15.4

51.9 ± 8.5

19.7 ± 1.6

78%

2.2 ± 0.7

8.0E–03

4.4E–03

—

RASSF2

Ras association (RalGDS/AF-6) domain family 2

D79990

20pter–p12.1

29.3 ± 4.5

12.3 ± 1.7

56%

2.1 ± 0.6

4.3E–01

3.7E–03

—

NEDD8

Neural precursor cell expressed, developmentally down-regulated 8

D23662

14q11.2

53.1 ± 6.8

23.8 ± 2.6

67%

2.0 ± 0.5

1.9E–01

8.6E–04

—

CAP1

CAP, adenylate cyclase-associated protein 1

L12168

1p34.2

134.7 ± 18.9

58.4 ± 5.4

67%

2.1 ± 0.5

4.2E–02

3.1E–03

—

ZAP70

Zeta-chain (TCR) associated protein kinase

L05148

2q12

36.6 ± 4.3

16.3 ± 1.4

78%

2.0 ± 0.4

4.4E–02

5.1E–04

—

FKBP8

FK506 binding protein 8

L37033

19p12

27.4 ± 3.7

12.3 ± 1.1

56%

2.0 ± 0.5

1.4E–02

7.6E–04

—

GRK6

G protein-coupled receptor kinase 6

L16862

5q35

23.4 ± 3.6

10.5 ± 1.0

56%

2.0 ± 0.5

3.0E–02

1.3E–03

—

MAP2K2

Mitogen-activated protein kinase kinase 2

L11285

7q32

29.1 ± 4.0

12.9 ± 0.7

67%

2.0 ± 0.5

1.5E–02

1.3E–03

—

PTP4A2

Protein tyrosine phosphatase type IVA, member 2

U14603

1p35

76.6 ± 9.4

35.3 ± 2.6

56%

1.9 ± 0.4

2.0E–02

5.7E–04

—

RAC1

Ras-related C3 botulinum toxin substrate 1

NM_006908

7p22

20.1 ± 3.4

8.9 ± 0.6

56%

2.0 ± 0.5

3.4E–02

3.2E–03

—

MX2

Myxovirus (influenza virus) resistance 2

M30818

21q22.3

20.6 ± 3.9

8.7 ± 0.9

56%

1.9 ± 0.7

7.0E–01

8.6E–03

—

FYB

FYN binding protein (FYB-120/130)

U93049

5p13.1

5.2 ± 0.7

10.8 ± 1.9

67%

−2.3 ± 0.2

4.3E–01

7.1E–03

—

Structural

MYL9

Myosin, light polypeptide 9, regulatory

J02854

20q 11.23

17.9 ± 4.7

4.4 ± 0.2

67%

4.1 ± 1.1*

1.4E–01

1.1E–03

—

PLEC1

Plectin 1, intermediate filament binding protein

U53204

8q24

37.8 ± 6.0

9.6 ± 0.9

78%

3.9 ± 0.6

3.0E–02

3.4E–05

2.8E–03

GFAP

Glial fibrillary acidic protein

S40719

17q21

19.9 ± 3.2

7.2 ± 0.5

67%

2.8 ± 0.4

1.9E–01

3.5E–04

—

BECN1

Beclin 1

L38932

17q21

40.3 ± 4.0

14.8 ± 1.2

78%

2.7 ± 0.3

5.7E–02

1.6E–05

7.4E–04

MYH9

Myosin, heavy polypeptide 9, non-muscle

M31013

22q13.1

149.8 ± 13.7

55.4 ± 4.4

78%

2.7 ± 0.2

5.8E–02

6.7E–06

1.9E–04

KRT1

Keratin 1

M98776

12q12–q13

16.7 ± 2.9

6.2 ± 0.3

67%

2.5 ± 0.6

4.9E–01

3.0E–03

—

NUMA1

Nuclear mitotic apparatus protein 1

Z14227

11q13

25.7 ± 3.4

9.5 ± 0.6

78%

2.7 ± 0.4

5.5E–02

3.4E–04

—

PDLIM1

PDZ and UM domain 1 (elfin)

U90878

10q22–q26.3

26.6 ± 2.9

11.0 ± 0.8

56%

2.4 ± 0.3

3.6E–02

2.5E–05

1.6E–03

MYL6

Myosin, light polypeptide 6, alkali, smooth muscle and non-muscle

M31212

12

360.2 ± 18.0

138.0 ± 13.6

89%

2.6 ± 0.1

2.4E–02

3.9E–06

8.1E–05

SAFB

Scaffold attachment factor B

L43631

19p13.3–p13.2

25.4 ± 2.6

10.3 ± 0.7

67%

2.5 ± 0.3

9.9E–02

2.8E–05

1.9E–03

MAPT

Microtubule-associated protein tau

AH005895

17q21.1

26.3 ± 4.6

10.1 ± 0.8

56%

2.4 ± 0.6

9.5E–02

2.2E–03

—

TPM3

Tropomyosin 3

BC000771

149.2 ± 16.9

64.5 ± 5.5

67%

2.3 ± 0.3

7.7E–02

1.7E–04

2.9E–02

HSU34301

Nonmuscle myosin heavy chain IIB

U34301

17

17.0 ± 2.1

7.4 ± 0.9

56%

2.3 ± 0.3

1.0E–01

1.2E–04

1.7E–02

KNS2

Kinesin 2 60/70kDa

L04733

14q32.3

16.1 ± 2.2

6.5 ± 0.4

56%

2.5 ± 0.3

6.5E–02

1.6E–04

2.4E–02

TUBB2C

Tubulin, β 2C

AK026167

9q34

53.2 ± 4.8

23.9 ± 2.5

67%

2.2 ± 0.2

1.7E–01

3.9E–05

3.2E–03

TUBA3

Tubulin, α 3

X01703

12q12–12q14.3

37.7 ± 5.5

14.5 ± 1.8

67%

2.4 ± 0.5

3.2E–01

9.7E–04

—

TNNC1

Troponin C, slow

M37984

3p21.3–p14.3

11.2± 1.2

5.1 ± 0.1

56%

2.2 ± 0.2*

6.7E–02

1.7E–04

2.7E–02

MSN

Moesin

M69066

Xq11.2–q12

178.8 ± 27.9

72.8 ± 6.9

67%

2.2 ± 0.6

5.4E–02

4.1 E–03

—

Transcription

RELA

V-rel reticuloendotheliosis viral oncogene homolog A

L19067

11q13

39.8 ± 4.3

11.1 ± 1.1

100%

3.6 ± 0.4

4.1E–03

7.9E–07

4.8E–06

1.964

FOS

V-fos FBJ murine osteosarcoma viral oncogene homolog

V01512

14q24.3

51.4 ± 14.0

13.9 ± 3.4

67%

3.4 ± 1.1

2.8E–02

4.5E–03

—

NFE2

Nuclear factor (erythroid-derived 2)

S77763

12q13

32.3 ± 4.1

9.5 ± 1.4

78%

3.4 ± 0.4

3.5E–01

1.5E–05

6.1 E–04

IRF5

Interferon regulatory factor 5

U51127

7q32

29.0 ± 4.6

10.2 ± 1.0

78%

2.9 ± 0.5

8.4E–02

2.0E–04

3.6E–02

ZNFpT1

Zinc-finger protein

X65230

15.2 ± 2.2

5.3 ± 0.1

78%

2.9 ± 0.4

6.4E–02

5.9E–04

—

SF1

Splicing factor 1

L49380

11q13

46.4 ± 4.3

16.2 ± 0.6

78%

2.9 ± 0.3

3.7E–02

1.5E–05

6.4E–04

2.307

HCFC1

Host cell factor C1

L20010

Xq28

26.0 ± 2.9

8.9 ± 0.5

78%

2.9 ± 0.3

2.7E–02

2.5E–05

1.6E–03

SREBF1

Sterol regulatory element binding transcription factor 1

U00968

17p11.2

25.6 ± 2.1

8.9 ± 0.6

89%

2.9 ± 0.2

6.3E–02

1.6E–06

1.9E–05

2.019

POLR2A

Polymerase (RNA) II (DNA directed) polypeptide A

X74874

17p13.1

18.9 ± 2.7

6.8 ± 0.5

67%

2.8 ± 0.4

7.3E–02

7.7E–05

8.7E–03

MAZ

MYC-associated zinc finger protein

M94046

16p11.2

29.7 ± 3.1

10.7 ± 0.6

78%

2.8 ± 0.3

7.9E–03

3.1E–05

2.3E–03

TCFL1

Transcription factor-like 1

D43642

1q21

38.2 ± 5.3

14.3 ± 0.7

67%

2.7 ± 0.4

9.9E–02

4.7E–04

—

IRF3

Interferon regulatory factor 3

Z56281

19q13.3–q13.4

25.1 ± 1.7

9.5 ± 0.5

78%

2.6 ± 0.2

2.2E–02

9.3E–07

6.5E–06

2.303

BTG2

BTG family, member 2

U72649

1q32

40.3 ± 8.1

14.8 ± 1.1

67%

2.5 ± 0.7

8.1E–02

3.0E–03

—

VGLL4

Vestigial like 4

D50911

3p25.2

16.4 ± 2.1

6.5 ± 0.3

67%

2.5 ± 0.3

1.3E–01

3.1 E–04

—

RNPC2

RNA-binding region (RNP1. RRM) containing 2

L10910

20q11.23

16.1 ± 2.1

6.4 ± 0.6

67%

2.5 ± 0.3

2.4E–01

4.7E–04

—

NBL1

Neuroblastoma, suppression of tumorigenicity 1

D28124

1p36.13–p36.11

16.6 ± 1.9

6.8 ± 0.6

67%

2.4 ± 0.3

2.4E–01

1.2E–04

1.6E–02

NCOR2

Nuclear receptor co-repressor 2

U37146

12q24

26.6 ± 2.9

11.2 ± 0.8

67%

2.4 ± 0.3

4.2E–02

5.1E–05

5.0E–03

JUND

Jun D proto-oncogene

X56681

19p13.2

114.4 ± 9.6

47.5 ± 3.9

89%

2.4 ± 0.2

1.4E–02

3.0E–06

4.8E–05

TRIM28

Tripartite motif-containing 28

U95040

19q13.4

44.0 ± 5.2

17.3 ± 1.2

67%

2.3 ± 0.5

1.4E–02

2.2E–04

4.0E–02

POLR2E

Polymerase (RNA) II (DNA directed) polypeptide E

D38251

19p13.3

28.4 ± 3.5

11.2 ± 1.1

78%

2.3 ± 0.5

7.7E–02

6.5E–04

—

BCL6

B-cell CLL/lymphoma 6 (zinc finger protein 51)

U00115

3q27

12.0 ± 2.1

5.2 ± 0.2

56%

2.3 ± 0.4

5.3E–02

2.6E–03

—

PML

Promyelocytic leukemia

M79462

15q22

10.7 ± 1.3

4.7 ± 0.2

56%

2.3 ± 0.3*

1.5E–02

5.1 E–04

—

CEBPB

CCAAT/enhancer binding protein (C/EBP), β

X52560

20

80.6 ± 14.7

32.2 ± 2.9

67%

2.2 ± 0.7

3.7E–01

1.3E–02

—

SFRS11

Splicing factor, arginine/serine-rich 11

M74002

1p31

20.0 ± 2.3

8.4 ± 0.8

78%

2.2 ± 0.5

1.4E–01

3.4E–04

—

SRF

Serum response factor

J03161

6p21.1

18.6 ± 2.5

8.3 ± 0.6

56%

2.2 ± 0.3

1.7E–01

3.9E–04

—

YY1

YY1 transcription factor

M77698

14q

13.4 ± 1.5

6.3 ± 0.6

56%

2.1 ± 0.2

2.2E–01

2.8E–04

—

LYL1

Lymphoblastic leukemia derived sequence 1

M22638

19p13.2

14.2 ± 1.2

6.8 ± 0.3

56%

2.1 ± 0.2

4.2E–02

4.3E–05

3.7E–03

SUPT4H1

Suppressor of Ty 4 homolog 1

U43923

17q21–q23

20.1 ± 3.2

8.9 ± 0.8

56%

2.0 ± 0.5

2.1E–01

2.9E–03

—

TAF15

TAF15 RNA polymerase II

U51334

17q11.1–q11.2

23.9 ± 2.8

11.1 ± 1.0

67%

1.9 ± 0.4

3.9E–02

6.5E–04

—

Translation

EIF3S9

Eukaryotic translation initiation factor 3, subunit 9 eta

U78525

7p22.3

19.6 ± 2.2

9.0 ± 0.7

67%

2.2 ± 0.2

2.3E–02

2.6E–04

4.8E–02

Transport

TCIRG1

T-cell, immune regulator 1, ATPase, H + transporting, lysosomal V0 protein a isoform 3

U45285

11q13.4–q13.5

31.4 ± 3.3

6.7 ± 0.5

100%

4.7 ± 0.5

1.2E–01

1.6E–07

1.6E–07

2.728

TETRAN

Tetracycline transporter-like protein

L11669

4p16.3

26.8 ± 2.7

6.8 ± 0.5

100%

3.9 ± 0.4

1.2E–01

1.6E–06

1.8E–05

2.404

HD

Huntingtin (Huntington disease)

L12392

4p16.3

22.3 ± 2.7

6.5 ± 0.3

78%

3.5 ± 0.4

9.1E–02

4.9E–05

4.6E–03

2.082

ATP6AP1

Human mRNA for ORF, Xq terminal portion

D16469

Xq28

31.7 ± 4.2

9.0 ± 0.8

89%

3.5 ± 0.5

6.5E–02

8.8E–06

2.9E–04

GGA3

Golgi associated, γ adaptin ear containing, ARF binding protein 3

D63876

17q25.2

33.9 ± 3.3

10.1 ± 0.6

89%

3.4 ± 0.3

7.1E–02

2.3E–06

3.2E–05

2.236

ATP6V0C

ATPase, H + transporting, lysosomal, VO subunit c

M62762

16p13.3

69.7 ± 8.8

21.2 ± 1.9

89%

3.3 ± 0.4

9.8E–02

4.3E–05

3.7E–03

AP2M1

Adaptor-related protein complex 2, mu 1 subunit

D63475

3q28

42.6 ± 5.5

14.2 ± 1.3

67%

3.0 ± 0.4

4.1E–02

1.3E–04

1.8E–02

SLC2A3

Solute carrier family 2 (facilitated glucose transporter), member 3

M20681

12p13.3

26.0 ± 2.3

9.3 ± 1.0

89%

2.8 ± 0.2

1.3E–01

9.2E–06

3.3E–04

SLC9A1

Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na + /H +, amiloride sensitive)

S68616

1p36.1–p35

19.0 ± 2.4

6.8 ± 0.2

67%

2.8 ± 0.4

4.2E–02

2.3E–04

4.2E–02

SLC11A1

Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1

D50402

2q35

19.1 ± 3.0

6.8 ± 0.6

78%

2.8 ± 0.4

1.9E–01

4.7E–04

—

MLC1

Megalencephalic leukoencephalopathy with subcortical cysts 1

D25217

22q13.33

16.1 ± 2.6

5.8 ± 0.5

56%

2.8 ± 0.4*

2.2E–02

5.7E–04

—

SEC24C

FLJ44715 gene product

D38555

10q22.3

21.3 ± 2.9

8.0 ± 0.6

67%

2.7 ± 0.4

8.3E–02

3.3E–04

—

CLTA

Clathrin, light polypeptide (Lea)

M20471

9p13

73.6 ± 9.1

26.7 ± 1.9

89%

2.8 ± 0.3

4.6E–02

3.8E–05

3.2E–03

AP2B1

Adaptor-related protein complex 2, β 1 subunit

M34175

17q11.2–q12

28.2 ± 4.0

10.3 ± 1.2

67%

2.5 ± 0.5

1.7E–01

2.3E–04

4.2E–02

AP1B1

Adaptor-related protein complex 1, β 1 subunit

L13939

22q12.2

23.2 ± 3.0

9.5 ± 0.8

67%

2.4 ± 0.3

4.3E–02

6.1E–04

—

TXN2

Thioredoxin 2

U78678

22q13.1

18.9 ± 2.5

7.5 ± 0.5

67%

2.5 ± 0.3

3.8E–02

2.8E–04

—

CRIP1

Cysteine-rich protein 1 (intestinal)

U09770

7q11.23

35.3 ± 3.9

15.9 ± 1.1

56%

2.2 ± 0.2

9.2E–02

1.4E–04

2.0E–02

NAPA

N-ethylmaleimide-sensitive factor attachment protein, alpha

U39412

19q13.33

15.0 ± 2.0

6.4 ± 0.4

67%

2.1 ± 0.5

5.5E–02

3.2E–03

—

Ubiquitin

UBE1

Ubiquitin-activating enzyme E1

M58028

Xp11.23

46.4 ± 6.9

11.3 ± 1.0

89%

4.1 ± 0.6

8.6E–03

3.3E–05

2.5E–03

USP11

Ubiquitin specific protease 11

U44839

Xp11.23

60.2 ± 7.4

18.9 ± 1.1

78%

3.2 ± 0.4

1.2E–02

5.0E–05

4.9E–03

UBC

Ubiquitin

M26880

12q24.3

198.0 ± 14.3